Personalized 'Living Drug' trial targets Tough-to-Treat kidney cancer
Disease control
Ongoing
This study is testing a new cell therapy called AB-2100 for people with advanced kidney cancer that has come back or spread after standard treatments. Doctors take a patient's own immune cells, genetically modify them to better recognize and attack cancer, and infuse them back in…
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC